Millennium Management LLC Purchases 255,086 Shares of Audentes Therapeutics Inc (NASDAQ:BOLD)

Share on StockTwits

Millennium Management LLC raised its position in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 49.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 773,279 shares of the biotechnology company’s stock after buying an additional 255,086 shares during the quarter. Millennium Management LLC owned about 1.69% of Audentes Therapeutics worth $21,721,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BOLD. SG Americas Securities LLC raised its stake in shares of Audentes Therapeutics by 1,405.3% during the 2nd quarter. SG Americas Securities LLC now owns 109,920 shares of the biotechnology company’s stock worth $4,162,000 after acquiring an additional 102,618 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Audentes Therapeutics by 50.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,005 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in shares of Audentes Therapeutics during the 2nd quarter valued at $745,000. Aperio Group LLC purchased a new stake in shares of Audentes Therapeutics during the 2nd quarter valued at $46,000. Finally, Public Employees Retirement Association of Colorado purchased a new stake in shares of Audentes Therapeutics during the 2nd quarter valued at $354,000. Institutional investors and hedge funds own 98.08% of the company’s stock.

Several research analysts recently weighed in on the company. ValuEngine downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $48.00 target price on shares of Audentes Therapeutics in a research report on Friday, November 8th. Evercore ISI upgraded Audentes Therapeutics from an “in-line” rating to an “outperform” rating in a research note on Wednesday, November 27th. Robert W. Baird started coverage on Audentes Therapeutics in a report on Wednesday, October 2nd. They issued an “underperform” rating and a $10.00 price target for the company. Finally, William Blair restated a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the stock. Audentes Therapeutics has a consensus rating of “Hold” and a consensus target price of $42.00.

In other news, CEO Matthew R. Patterson sold 14,426 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $30.00, for a total value of $432,780.00. Following the sale, the chief executive officer now directly owns 127,820 shares of the company’s stock, valued at approximately $3,834,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Louis G. Lange sold 10,000 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the completion of the sale, the director now owns 276,044 shares in the company, valued at approximately $8,877,575.04. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.

Shares of BOLD stock opened at $28.61 on Tuesday. The business has a fifty day moving average of $27.71 and a 200 day moving average of $33.11. Audentes Therapeutics Inc has a 1 year low of $17.95 and a 1 year high of $41.65. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -8.41 and a beta of 1.77.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.07. During the same period in the previous year, the company posted ($0.97) EPS. Equities analysts predict that Audentes Therapeutics Inc will post -4.13 earnings per share for the current year.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Euro STOXX 50 Index

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.